×
About 181,193 results

A Prospective Observational Cohort to Study the Genetics of Obstructive Sleep Apnea and Associated Co-Morbidities
https://clinicaltrials.gov/ct2/show/NCT01857427

Jan 21st, 2022 - The purpose of building the cohort is to allow the performance of genome-wide association studies with a large sample of patients that have been well-characterized using standardized procedures.

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT03539536

Jan 21st, 2022 - This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2).

A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours
https://clinicaltrials.gov/ct2/show/NCT03468426

Jan 21st, 2022 - This study has 2 parts. The first part was open to adults with advanced non-small cell lung cancer. The second part was open also to adults with other types of advanced cancer of the lung, brain, skin, and liver. After early encouraging results, more people with liver cancer can now take part in the study. The participants get a combination of two medicines called BI 836880 and ezabenlimab. BI ...

Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium (PROMIS II)
https://clinicaltrials.gov/ct2/show/NCT03460704

Jan 21st, 2022 - The primary objective of the trial is to investigate the effect of the use of inhaled colistimethate sodium, administered twice daily via the I-neb for 12 months, compared to placebo in subjects with non-cystic fibrosis bronchiectasis (NCFB) chronically infected with P. aeruginosa on the frequency of pulmonary exacerbations.

Preoperative Inspiratory Muscle Training
https://clinicaltrials.gov/ct2/show/NCT04423614

Jan 21st, 2022 - Highly active muscles such as the diaphragm are particularly sensitive to both disuse and training. For example, diaphragm fibers of controlled mechanically ventilated young adults atrophy by more than 50% within 36 hours of complete inactivity, and mechanical ventilation (MV) initiates signaling pathways within the first several hours of inactivity that promote progressive diaphragmatic fiber ...

Blood Sampling Functionality of Extended Dwell Catheters
https://clinicaltrials.gov/ct2/show/NCT04409418

Jan 21st, 2022 - Many patients will require ongoing blood draws for laboratory testing while in the hospital and hospitals generally avoid using peripheral IVs for laboratory testing as it is associated with an increase in complications such as irritation and infiltration (where the IV medication or fluid will leak out of the vein and into the surrounding tissue). Therefore, patients are often required to have ...

A Longitudinal Study of COVID-19 Sequelae and Immunity
https://clinicaltrials.gov/ct2/show/NCT04411147

Jan 21st, 2022 - Coronavirus disease-2019 (COVID-19) is a newly recognized viral disease primarily involving the respiratory tract. The world is currently experiencing COVID-19 pandemic with a significant portion of those infected developing severe disease manifestations including pneumonia, acute respiratory distress syndrome with respiratory failure, and, in some cases, death. The clinical characteristics and...

Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea
https://clinicaltrials.gov/ct2/show/NCT02727933

Jan 21st, 2022 - The primary objective of this study is to describe the safety of the combination of Daklinza (daclatasvir) and Sunvepra (asunaprevir) when used for the treatment of chronic hepatitis C (CHC) genotype 1b patients in real-life conditions when used according to its registered indications.

Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
https://clinicaltrials.gov/ct2/show/NCT04467723

Jan 21st, 2022 - The purpose of this study is to see if adding pirfenidone to atezolizumab will increase anti tumor activity and reduce treatment resistance in stage 4 and recurrent non- small cell lung cancer participants.

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
https://clinicaltrials.gov/ct2/show/NCT04402788

Jan 21st, 2022 - PRIMARY OBJECTIVES: I. To compare investigator-assessed progression free survival (PFS) between atezolizumab plus radiotherapy and atezolizumab alone. (Phase II) II. To compare overall survival (OS) between atezolizumab plus radiotherapy and atezolizumab alone. (Phase III) SECONDARY OBJECTIVES: I. To assess the toxicity between the atezolizumab plus radiotherapy arm and the atezolizumab arm. II...

Investigating a Vaccine Against COVID-19
https://clinicaltrials.gov/ct2/show/NCT04400838

Jan 21st, 2022 - There will be 12 study groups and it is anticipated that a total of 12,390 volunteers will be enrolled. Groups 1, 7 & 9 are adults aged 56-69 years; groups 2, 8 & 10 are adults 70 years and over; groups 4, 5 & 6 are adults aged 18-55 years; group 11 is adults aged 18-55 years who have previously received a ChAdOx vectored vaccine; group 12 is HIV positive adults aged 18-55 years. The vaccine wi...

A Study of Brexanolone for Acute Respiratory Distress Syndrome Due to COVID-19
https://clinicaltrials.gov/ct2/show/NCT04537806

Jan 21st, 2022 - The purpose of this study is to evaluate the efficacy and safety of brexanolone in participants on ventilator support for acute respiratory distress syndrome (ARDS) due to COVID-19.

ACTIV-3: Therapeutics for Inpatients With COVID-19
https://clinicaltrials.gov/ct2/show/NCT04501978

Jan 21st, 2022 - This is a master protocol to evaluate the safety and efficacy of multiple investigational agents aimed at modifying the host immune response to SARS-CoV-2 infection, or directly enhancing viral control in order to limit disease progression. The protocol is for a randomized, blinded, controlled platform study that allows investigational drugs to be added and dropped during the course of the stud...

INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure
https://clinicaltrials.gov/ct2/show/NCT02787044

Jan 21st, 2022 - Influenza leads to significant morbidity and mortality, particularly in patients with cardiovascular disease. Influenza-related death is more common in patients with cardiovascular disease than any other chronic health condition. Influenza infection has been temporally associated with acute cardiovascular events, such as acute coronary syndrome and acute heart failure. Due to the increased risk...

Dose Escalation by Boosting Radiation Dose Within the Primary Tumor Using FDG-PET-CT Scan in Stage IB, II and III NSCLC
https://clinicaltrials.gov/ct2/show/NCT01024829

Jan 21st, 2022 - A randomized phase II study will be conducted in patients with inoperable stage IB, II or III non-small cell lung cancer (NSCLC). The patients will be randomized to receive the standard 66 Gy given in 24 fractions of 2.75 Gy with an integrated boost to the primary tumor as a whole (Arm A) or with an integrated boost to the 50% SUVmax area of the primary tumor (of the pre-treatment FDG-PET scan)...

HFNC Initiation Flow Rate Study
https://clinicaltrials.gov/ct2/show/NCT04517344

Jan 21st, 2022 - The investigators propose an open label, non-blinded, single center randomized controlled feasibility study to find the optimal initial HFNC flow rate in children less than 12 months old with clinically diagnosed moderate to severe bronchiolitis. This feasibility study is projected to take 6 months over the Winter/Spring of 2020-2021. The study is consisted of 3 arms, comparing HFNC therapy at ...

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
https://clinicaltrials.gov/ct2/show/NCT04491942

Jan 21st, 2022 - PRIMARY OBJECTIVES: I. To establish the safety and tolerability of the combination of cisplatin + ATR kinase inhibitor BAY1895344 (BAY 1895344) in patients with advanced solid tumors. II. To establish the safety and tolerability of the combination of cisplatin + gemcitabine + BAY 1895344 in patients with advanced solid tumors with an emphasis on urothelial carcinoma (UC). III. To establish the ...

Pretomanid in Adults With Hepatic Impairment
https://clinicaltrials.gov/ct2/show/NCT02422524

Jan 21st, 2022 - This is a Phase 1, single dose (200 mg), open-label, sequential group study comparing the pharmacokinetics and safety of Pretomanid in subjects with mild, moderate, and severe hepatic impairment to matched, non-hepatically impaired subjects. This study will enroll approximately 6 subjects with mild hepatic impairment (Child-Pugh A), approximately 6 subjects with moderate hepatic impairment (Chi...

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT04214262

Jan 21st, 2022 - PRIMARY OBJECTIVE: I. To compare overall survival (OS) in patients with inoperable, early stage non-small cell lung cancer (NSCLC) randomized to stereotactic body radiation therapy (SBRT) with or without atezolizumab. SECONDARY OBJECTIVES: I. To compare investigator-assessed progression-free survival (IA-PFS) between the arms. II. To compare progression free survival (PFS) by blinded independen...

Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant
https://clinicaltrials.gov/ct2/show/NCT04239989

Jan 21st, 2022 - PRIMARY OBJECTIVE: I. To assess the safety of itacitinib in patients with bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplantation (HCT). SECONDARY OBJECTIVES: I. To assess treatment failure at 3 months and 6 months. II. To assess change in symptom-based lung score at 3 months and 6 months. III. To assess change in the St. George Respiratory Questionnaire and ...